Pharma Exports Grow 4.53% In August, Imports Grow 20%

New Delhi : Exports of pharmaceutical products from the country have reported a 4.53 per cent growth during the month of August compared to the same period of previous year. For the five months of the current fiscal year has posted a 4.18 per cent growth.

According to data from the Central Government, the exports during the month of August, 2023 stood at $2.24 billion as compared to $2.14 billion during the same month of last year.

The growth compared to the exports of $2.12 billion in the previous month of July is around 5.66 per cent.

For the five months from April to August, 2023, the exports were at $10.96 billion as compared to $10.52 billion reported during the same period of previous year.

Imports have reported a 20.08 per cent growth during the month of August, at $763 million as compared to $635 million registered during the same month of last year. The cumulative imports from April to August, 2023 declined marginally to $3.45 billion as compared to $3.46 billion during the same period of previous fiscal year.

The ministry of health and family welfare in June, this year, said that India’s drug and pharmaceutical products exports grew by 125 per cent from Rs. 90,415 crore in 2013-14 to Rs. 2,04,110 crore in 2022-23.

Drugs and pharmaceuticals exports constitute 5.71 per cent of the total exports from India. India ranks 3rd worldwide for the production of drugs and pharmaceuticals by volume exporting to around 200 countries/territories with the top 5 destinations being the USA, Belgium, South Africa, UK, and Brazil.

India accounts for 60 per cent of global vaccine production making it the largest vaccine producer in the world. India is also one of the biggest suppliers of low-cost vaccines in the world and is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume.

“Further, India has supplied over 298 million Covid-19 vaccines to around 100 countries across the globe under Vaccine Maitri initiative (till May 19, 2023),” said the Ministry. It added that an investment of Rs. 21,861 crore was received under PLI schemes till June.

Related Posts

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

Three arrested after liquor bottles found at pharma firm

Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

Three arrested after liquor bottles found at pharma firm

Three arrested after liquor bottles found at pharma firm

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources